温馨提示：本站仅提供公开网络链接索引服务，不存储、不篡改任何第三方内容，所有内容版权归原作者所有
AI智能索引来源：http://www.pr.com/press-release/907772
点击访问原文链接

Biomed Industries Announces Triple IGF-1/GLP-1/GIP Receptor Agonist NA-931 for Obesity - PR.com

进入原网站 导航首页
Biomed Industries Announces Triple IGF-1/GLP-1/GIP Receptor Agonist NA-931 for Obesity - PR.com Join Now Sign In Businesses Business Directory Products & Services Post Your Profile Press Releases Press Release Pricing Submit Press Release Press Release Distribution Recent Press Releases Become a Publishing Partner For Journalists Press Releases Businesses Products & Services Products Services Press Releases Submit Press Release ✕ Press Releases Press Release Pricing Submit Press Release Press Release Distribution Recent News Recent News News by Category News by US Region News by Country RSS News Feeds Business News Lifestyle News Public Interest News Technology News Become a Publishing Partner For Journalists Businesses Business Directory Products & Services Post Your Profile Join Now Sign In Press Release Pricing Recent News Business Lifestyle Public Interest Technology Press Release Pricing Create Account Press Release Pricing Submit Press Release Press Release Distribution Recent News Recent News News by Category News by US Region News by Country Become a Publishing Partner For Journalists RSS News Feeds Business News Lifestyle News Public Interest News Technology News Press Releases>Medical & Health>Biomed Industries Inc.> Biomed Industries Inc. Biomed Industries Inc. Press Releases More Biomed Industries Announces Triple IGF-1/GLP-1/GIP Receptor Agonist NA-931 for Obesity

A new drug for obesity that is both safe and effective.

Get Email Alert RSS San Jose, CA, March 13, 2024 --(PR.com)-- Biomed Industries, Inc. (Biomed), a leading biopharmaceutical company, announced its latest breakthrough in obesity treatment with the development of NA-931, a triple receptor agonist targeting IGF-1, GLP-1, and GIP hormones. Unlike current medications that focus solely on GLP-1 or a combination of GLP-1 and GIP, NA-931 represents a pioneering approach to weight loss therapy.

Biomed is presenting its research results at the upcoming international conferences: 17th International Conference on Childhood Obesity & Nutrition, March 14-15, 2024, London, UK; American Association of Clinical Endocrinology (AACE) Annual Conference, May 9-11, 2024, in New Orleans, Louisiana, USA; American Diabetes Association, June 21-24, Orlando, Florida, USA.

NA-931, formulated for oral administration, will be in Phase 2B clinical trials in the upcoming months. As a result of its novel triple action, NA-931 significantly reduces body fat while preserving muscle mass. Moreover, NA-931 demonstrates a notable reduction in other adverse events commonly associated with existing treatments.

“We have made a significant discovery as to the synergic actions of the three major growth hormone receptors and agonists that lead to the remarkable results of NA-931 for the treatment of obesity,” said Lloyd Tran, Founder and CEO of Biomed Industries, Inc. He added, "This research, spanning over two decades, has yielded breakthroughs in various disease areas, including Alzheimer's Disease, ALS, Major Depressive Disorder, and rare conditions such as Rett Syndrome and Fragile X. This innovative platform holds promise for developing novel therapies for neurological and metabolic diseases, for which there are no viable treatments currently."

About Biomed Industries, Inc.:

Biomed Industries, Inc. is a pioneering biopharmaceutical company dedicated to developing and commercializing novel drug therapeutics to address unmet medical needs. The company's research team has developed a new platform of drugs targeting Alzheimer's disease, ALS, Major Depressive Disorder (MDD), Diabetes, Obesity, Metabolic dysfunction-associated steatohepatitis (MASH), and rare diseases, including Rett Syndrome and Fragile X.

For further information, please visit Biomed Industries' official website: https://www.biomedind.com Contact Biomed Industries, Inc.
Michael Willis
800-824-5135
www.biomedind.com Contact Categories Medical & Health PR.com Press Release Distribution Submit Press Release Press Release Pricing Press Release Distribution Account Create Free Account Post Your Profile Resources Recent News RSS News Feeds For Journalists Articles Company About Contact Become a Publishing Partner Terms Privacy © 2026 PR.com and its licensors Terms Privacy Follow PR.com

智能索引记录